Zacks Investment Research
19 Jun 2026, 15:36 UTC · 2h ago
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 15:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
10x Genomics (TXG) has entered into a multi-year research collaboration with the Cleveland Clinic to develop novel diagnostic applications for bladder cancer. — Entering the clinical diagnostic market expands the company's total addressable market beyond core research, creating long-term revenue growth potential.
+0.40The collaboration will utilize TXG's Flex Apex and Xenium platforms, with potential expansion to the Atera platform, to identify biomarkers for cancer therapies. — Validation of these specific technology platforms in a clinical setting increases their commercial viability and adoption rates in precision oncology.
+0.30TXG shares have traded flat since the announcement of the collaboration on Wednesday. — The market has already priced in the news, resulting in no immediate price movement.
+0.00Which stocks this story touches
Continue reading
6 related stories
Search tags
The company entered a multi-year research collaboration with Cleveland Clinic, strengthening its long-term growth prospects and market position in precision oncology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
4h ago
